We have located links that may give you full text access.
Azathioprine and Mycophenolate Mofetil Adherence Patterns and Predictors among Medicaid Beneficiaries with Systemic Lupus Erythematosus.
Arthritis Care & Research 2018 October 25
OBJECTIVE: Azathioprine (AZA) and mycophenolate mofetil (MMF) are frequently used immunosuppressives for moderate-to-severe SLE. We studied longitudinal patterns and predictors of adherence to AZA and MMF in a nationwide U.S. SLE cohort.
METHODS: In the Medicaid Analytic eXtract (2000-2010), we identified SLE patients who initiated AZA or MMF (no use in prior 6 months) with >12 months of continuous follow-up. We dichotomized adherence at 80% with >24/30 days/month considered adherent. We used group-based trajectory models to estimate monthly adherence patterns and multivariable multinomial logistic regression to determine the association between demographic, SLE and utilization-related predictors and the odds ratios (OR) of belonging to a nonadherent vs. the adherent trajectory, separately for AZA and MMF.
RESULTS: We identified 2,309 AZA initiators and 2,070 MMF initiators with SLE. Four-group trajectory models classified 17% of AZA and 21% of MMF initiators as adherent. AZA and MMF nonadherers followed similar trajectory patterns. Black race (OR 1.67, 95% CI 1.20-2.31) and Hispanic ethnicity (OR 1.58, 95% CI 1.06-2.35) increased odds of AZA nonadherence; there were no significant associations between race/ethnicity and MMF nonadherence. Male sex and polypharmacy were associated with lower odds of nonadherence to both medications; lupus nephritis was associated with lower odds of nonadherence to MMF (OR 0.74, 95% CI 0.55-0.99).
CONCLUSIONS: Adherence to AZA or MMF over the first year of use was rare. Race, sex and lupus nephritis were modestly associated with adherence, but the magnitude, direction and significance of predictors differed by medication suggesting the complexity of predicting adherence behavior. This article is protected by copyright. All rights reserved.
METHODS: In the Medicaid Analytic eXtract (2000-2010), we identified SLE patients who initiated AZA or MMF (no use in prior 6 months) with >12 months of continuous follow-up. We dichotomized adherence at 80% with >24/30 days/month considered adherent. We used group-based trajectory models to estimate monthly adherence patterns and multivariable multinomial logistic regression to determine the association between demographic, SLE and utilization-related predictors and the odds ratios (OR) of belonging to a nonadherent vs. the adherent trajectory, separately for AZA and MMF.
RESULTS: We identified 2,309 AZA initiators and 2,070 MMF initiators with SLE. Four-group trajectory models classified 17% of AZA and 21% of MMF initiators as adherent. AZA and MMF nonadherers followed similar trajectory patterns. Black race (OR 1.67, 95% CI 1.20-2.31) and Hispanic ethnicity (OR 1.58, 95% CI 1.06-2.35) increased odds of AZA nonadherence; there were no significant associations between race/ethnicity and MMF nonadherence. Male sex and polypharmacy were associated with lower odds of nonadherence to both medications; lupus nephritis was associated with lower odds of nonadherence to MMF (OR 0.74, 95% CI 0.55-0.99).
CONCLUSIONS: Adherence to AZA or MMF over the first year of use was rare. Race, sex and lupus nephritis were modestly associated with adherence, but the magnitude, direction and significance of predictors differed by medication suggesting the complexity of predicting adherence behavior. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app